Paliperidone is NOT FDA-approved for adjunctive treatment of major depressive disorder
Paliperidone is FDA-approved only for schizophrenia (adults and adolescents ≥12 years) and schizoaffective disorder (as monotherapy or adjunctive to mood stabilizers/antidepressants), but NOT for major depressive disorder. 1
FDA-Approved Indications for Paliperidone
According to the FDA drug label, paliperidone's approved uses are strictly limited to:
- Schizophrenia in adults and adolescents (12-17 years)
- Schizoaffective disorder in adults (either as monotherapy OR as adjunctive therapy to mood stabilizers and/or antidepressants)
The key distinction here is that while paliperidone can be used adjunctively in schizoaffective disorder (which includes mood symptoms), this is fundamentally different from major depressive disorder 1.
FDA-Approved Atypical Antipsychotics for MDD Adjunctive Treatment
For adjunctive treatment of major depressive disorder specifically, the FDA has approved only certain atypical antipsychotics:
- Aripiprazole (approved as augmentation for MDD) 2
- Brexpiprazole (approved as augmentation for MDD) 3
- Quetiapine XR (approved as augmentation for MDD) 2
- Olanzapine/fluoxetine combination (approved for MDD) 2
Notably absent from this list is paliperidone 2.
Clinical Evidence Context
While paliperidone has been studied in bipolar disorder with some efficacy signals 4, 5, and research suggests it may have antidepressant properties in preclinical studies 6, no clinical trials have established its efficacy or safety specifically for major depressive disorder 2. The 2012 systematic review explicitly noted that "no clinical trials were found for off-label use" of paliperidone in depression-related conditions 2.
Clinical Implications
If you are considering adjunctive treatment for a patient with treatment-resistant major depressive disorder, use FDA-approved options: aripiprazole, brexpiprazole, quetiapine XR, or olanzapine/fluoxetine combination 7, 8, 7, 9, 10. These have established efficacy and safety data specifically in MDD populations.
Using paliperidone for MDD would constitute off-label use without supporting clinical trial evidence, exposing patients to risks (extrapyramidal symptoms, hyperprolactinemia, metabolic effects, orthostatic hypotension) 1 without demonstrated benefit in this population.